Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by Accountprinceon Jul 31, 2021 3:12pm
274 Views
Post# 33637305

Insider Buys through Recent Offering

Insider Buys through Recent OfferingJust saw that some of the bought deal units were picked up by insiders.  Kellum (58,824), Bihl (423,530) and Seto (176,470) for a total of 658,824.  Guess they wanted to avoid being diluted.

I still have a hard time understanding how they can trade when they have insider knowledge.  First, they know the Baxter deal which is fully redacted for public shareholders.  They know the details of the Tigris trial intimately whereas the best public shareholders have is it's "encouraging".  And they know the ins and outs of the Dialco marketing to potential partners along with how the process of FDA approval is going for home use.  The June 30 results are not public but must be known to them.  They must also know how the US listing process is going and who is interested in what stateside.

So how can they trade or acquire when they know all this information not yet known by public shareholders?  Anyone know what exempts them from what appears to be priveleged information but still they can buy?  Nice gig if you can get it.
<< Previous
Bullboard Posts
Next >>